Takara Bio Inc represents values of innovation, dedication, and collaboration in the field of biotechnology. With their corporate philosophy centered on contributing to society through the development of advanced technologies, Takara Bio Inc focuses on improving the quality of life and healthcare. The company aims to create value by delivering cutting-edge solutions and products that cater to diverse research needs, ranging from genetic analysis to regenerative medicine. Takara Bio Inc prioritizes customer satisfaction, sustainability, and responsible business practices, ensuring sustainable growth and development in the biotechnology industry.

Takara Bio Inc is primarily present in Japan, with its headquarters located in Kusatsu, Shiga. Apart from its domestic presence, the company also maintains a global presence with operations and subsidiaries in various countries and regions including the United States, Europe, China, and other Asian countries. Takara Bio Inc is a leading biotechnology company specializing in the development and distribution of life science research reagents, gene therapy products, and molecular diagnostics. With its extensive global reach, Takara Bio Inc continues to provide innovative solutions and contribute to advancements in the fields of genomics, stem cell research, and personalized medicine.

Takara Bio Inc, a leading biotechnology company, has achieved several significant milestones. They developed and commercialized various innovative products and technologies for life science research, including PCR and DNA sequencing systems. Takara Bio Inc played a pivotal role in advancing genetic engineering and molecular biology techniques worldwide. Additionally, they developed advanced stem cell technologies and contributed to significant breakthroughs in regenerative medicine. Moreover, the company successfully expanded its global presence by establishing subsidiaries and collaborations in various regions. With its continuous commitment to innovation and research, Takara Bio Inc remains at the forefront of the biotechnology industry, providing valuable solutions to researchers and scientists worldwide.

Takara Bio Inc is a leading biotechnology company based in Japan. Established in 1967, the company has a rich history and a strong background in the field. Takara Bio specializes in the development and manufacture of a wide range of innovative products and solutions for the life sciences industry. With a focus on advancing research and improving human health, Takara Bio has become synonymous with reliability and cutting-edge technology. Through its dedication to quality and customer satisfaction, the company has gained a global reputation as a trusted provider of biotechnology solutions.

The main competitors of Takara Bio Inc in the market are Thermo Fisher Scientific, Bio-Rad Laboratories, and QIAGEN.

Takara Bio Inc is primarily active in the life sciences industry. This Japanese company specializes in the development and manufacture of biotechnology products, including genomic research tools, reagents, and systems for areas such as genetic engineering, stem cell research, and diagnostics. Takara Bio Inc's innovative solutions and advanced technologies have made significant contributions to various fields of life sciences, including academic research, pharmaceutical development, and agricultural biotechnology. As a leader in the industry, Takara Bio Inc continuously strives to advance scientific knowledge and provide cutting-edge solutions for the global life sciences community.

The business model of Takara Bio Inc revolves around providing innovative biotechnology solutions and products to the global life science industry. Takara Bio Inc primarily focuses on the development and commercialization of technologies related to genetic engineering, biomolecular detection, and amplification, as well as stem cell research. The company offers a wide range of products, including reagents, enzymes, gene editing tools, and other molecular biology tools, catering to the needs of researchers, healthcare professionals, and pharmaceutical companies. Takara Bio Inc aims to contribute to advancements in areas such as personalized medicine, agriculture, and environmental conservation through its cutting-edge biotechnological solutions.

KGV kan for øyeblikket ikke beregnes for Takara Bio.

KUV kan for øyeblikket ikke beregnes for Takara Bio.

AlleAktien Kvalitetsscore kan for tiden ikke beregnes for Takara Bio.

Omsetningen kan for øyeblikket ikke beregnes for Takara Bio.

Resultatet kan for øyeblikket ikke beregnes for Takara Bio.

Takara Bio Inc is a leading company in the field of biotechnological research and development. The company specializes in the manufacturing and marketing of high-quality biological reagents and instruments that support a variety of research applications. The business model of Takara Bio Inc is based on providing products and services that assist researchers and scientific laboratories in carrying out their critical workflows. The company offers a wide range of reagents and instruments that focus on various applications such as gene expression, genotyping, proteome analysis, and cell culture. These products are sold worldwide to a variety of customers including pharmaceutical, biotech, and diagnostic companies, as well as public and private research institutions. Takara Bio Inc also has a research and development department that develops new and innovative products to provide solutions to customers and researchers. One such innovation is the SmartChip PCR system, a fully automated instrument that processes multiple samples simultaneously and is used to analyze gene expression profiles on a single chip. Another important area of focus for Takara Bio Inc is the manufacturing of mRNA-based therapeutics, which are used to combat diseases such as cancer. The company has already achieved significant success in this regard and has formed partnerships with other companies and research institutions to further advance. Takara Bio Inc divides its business model into three main divisions. The first division deals with the sale of reagents and instruments for genomic research and cellular analysis. Here, the company offers a wide range of reagents and kits to support DNA purification, PCR products, nanopore sequencing, amplification, genotyping and labeling, as well as plasmid minipreps and RNA isolation. The second division is the therapeutics division, which focuses on mRNA-based therapeutics and customized therapeutic vaccines to keep customers at the forefront of disease fighting in the biotech industry and clinical research. Takara Bio Inc has produced innovative methods for developing vaccines against cancer and other diseases. The third division is the service-oriented application technology, which assists customers in overcoming complex research challenges. The services include customized and technically sophisticated programs such as RNA sequencing, FACS assays, and ChIP sequencing. In summary, Takara Bio Inc is a company that focuses on biotechnological research and development. The business model of Takara Bio Inc includes the manufacturing and marketing of biological reagents and instruments that can be used in both basic research and clinical research and diagnostics. The three main divisions of Takara Bio Inc are the sale of reagents and instruments for genomic research and cellular analysis, the development of mRNA-based therapeutics, and services for customized application programs. With a strong focus on quality and innovation, Takara Bio Inc drives biotechnological research and development and is a leading company in this field.

Takara Bio utbetaler et dividende på 0 JPY fordelt over utdelinger i året.

Utbyttet kan for øyeblikket ikke beregnes for Takara Bio eller så utdeler ikke selskapet utbytte.

ISIN-en til Takara Bio er JP3460200003.

WKN for Takara Bio er A0DNGL.

Tikkeren til Takara Bio er 4974.T.

I løpet av de siste 12 månedene utbetalte Takara Bio et utbytte på . Dette tilsvarer en utbytteavkastning på ca. . For de neste 12 månedene vil Takara Bio sannsynligvis betale et utbytte på 19,79 JPY.

Utdelingsrendementet til Takara Bio er for øyeblikket .

Takara Bio betaler utbytte kvartalsvis. Dette blir utdelt i månedene , , , .

Takara Bio betalte utbytte hvert år de siste 16 årene.

For de kommende 12 månedene forventes det utbytter på 19,79 JPY. Dette tilsvarer en utbytteavkastning på 1,87 %.

Takara Bio tilordnes sektoren 'Helse'.

For å motta den siste utbyttet fra Takara Bio den på 17 JPY, måtte du ha aksjen i porteføljen din før ex-datoen den .

Utbetalingen av det siste utbyttet fant sted den .

I løpet av 2023 ble det utbetalt 42 JPY i utbytte fra Takara Bio.

Utdelingene fra Takara Bio blir betalt ut i JPY.